biote Corp. (BTMD) 股票分析

公司概述

Biote Corp. operates within the healthcare sector, specifically focusing on the medical care facilities industry where it functions as a practice-building entity in the hormone optimization space. The company's core business model involves training physicians and nurse practitioners to administer bioidentical hormone replacement pellet therapy to men and women suffering from hormonal imbalances. It offers a proprietary approach known as the Biote Method, which serves as the foundation for its service delivery and educational programs. With a market capitalization of $56.27M and an annual revenue of $192.22M, the company employs 223 individuals, positioning it as a mid-sized player with significant operational leverage in a niche therapeutic market.

财务健康

The company reported a trailing twelve-month revenue of $192.22M, generating a net income of $27.05M and an EBITDA of $37.54M. The substantial gap between the $192.22M in revenue and the $27.05M in net income reveals a cost structure where operating expenses and taxes consume approximately 86% of top-line sales, though the high gross margin mitigates this pressure. Biote Corp. generated $13.27M in free cash flow, indicating a robust ability to fund operations, repay debt, or pursue strategic initiatives without relying solely on external financing. The firm holds $24.12M in cash assets against a total debt load of $109.92M, resulting in a debt-to-equity ratio that is listed as N/A, suggesting the company utilizes significant leverage or has an equity structure that renders the standard ratio inapplicable. While the cash position provides immediate liquidity, the debt level of $109.92M must be managed carefully given the current cash reserves. The current ratio stands at 1.22, which indicates that the company possesses sufficient current assets to cover its short-term liabilities with a comfortable margin. Management effectiveness is highlighted by a return on assets of 19.1%, while the return on equity is listed as N/A, preventing a direct comparison of shareholder capital efficiency in the traditional sense.

估值评估

Biote Corp. trades with a trailing P/E ratio of 2.04 and a forward P/E of 2.65, implying that the market anticipates earnings growth or a multiple expansion that would justify the higher valuation expected in the future compared to historical performance. The price-to-book ratio is recorded at -0.79, a negative figure that indicates the company's market value is below its book value, often seen in capital-intensive firms or those with significant intangible asset write-downs, rather than reflecting a typical market premium. Alternative valuation metrics show a price-to-sales ratio of 0.29 and an EV/EBITDA of 3.74, suggesting the stock is priced at a fraction of its sales and generates significant earnings relative to enterprise value. The 52-week trading range spans from a low of $1.27 to a high of $4.75, meaning the current price sits within a wide historical band that reflects significant recent volatility. The beta value of 1.29 indicates that the stock price is more volatile than the broader market, moving approximately 29% more than the average stock in response to market fluctuations.

Growth & Income

Year-over-year revenue growth stands at -6.9%, while earnings growth has declined at a sharper rate of -36.7%, implying that earnings are contracting significantly faster than revenue, which points to potential margin compression or one-time expense impacts. As a non-dividend payer, the company does not distribute a dividend yield, maintaining a payout ratio of 0.0% as it reinvests its earnings into business operations rather than returning capital to shareholders. The overall growth and income profile characterizes Biote Corp. as a high-risk, high-revenue entity currently facing earnings contraction without the cushion of a dividend safety net.